EMA Authorised: Remsima (infliximab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA authorised Remsima (infliximab) from Celltrion Healthcare Hungary Kft. for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthriti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Remsima (infliximab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 12/03/2026